MedTrace Logo

Knee Steroid Injection and Blood Sugar Signatur

NCT04317404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2023-01-18

No results posted yet for this study

Summary

A prospective, observational study assessing the relationship between HbA1c level and the post-injection blood glucose signature. Participants will be non-diabetic, pre-diabetic, non-insulin dependent and insulin dependent type 2 diabetic patients who will be receiving a knee steroid injection. All of them will be consented a week prior to the injection, when the CGM sensor will be applied to the back of the upper arm. This will be removed a week after the injection. KOOS survey as well as VAS will be administered. Adverse events (e.g., change in medication or hospitalization) will be monitored throughout the study.

Conditions

Interventions

DRUG

40 mg Triamcinolone acetonide

Unilateral knee steroid injection

Sponsors & Collaborators

  • Foundation for Physical Medicine and Rehabilitation

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-11-30
Completion
2022-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04317404 on ClinicalTrials.gov